XyloCor Therapeutics adds Drs Fouad Azzam and Alan Colowick to Board along with raising $17m Series A financing co-led by Sofinnova Ventures and LSP
– USA, VA – XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, today announced the close of a $17 million Series A financing which was co-led by Sofinnova Ventures and LSP (Life Sciences Partners).…